Economic Advantages of Domestic Production of Biosimilar Medicines in Iran
Background: Biosimilars can be considered generic versions of branded biologic medicines. Substituting branded biologic medicines with biosimilars is important to reduce medication costs. In addition to reducing drug costs, the domestic production of biosimilars can provide many other economic benef...
Main Authors: | Nazila Yousefi, Behniya Azadmehr, Seyyed Ali Hashemi, Mohammadhossein Motevali Khameneh, Farzad Peiravian |
---|---|
Format: | Article |
Language: | fas |
Published: |
Shahid Sadoughi University of Medical Sciences
2023-09-01
|
Series: | Rāhburdhā-yi Mudīriyyat dar Niẓām-i Salāmat |
Subjects: | |
Online Access: | http://mshsj.ssu.ac.ir/article-1-653-en.pdf |
Similar Items
-
Biosimilars - advantages and prospects
by: A. A. Lidzhiyeva, et al.
Published: (2018-02-01) -
Biosimilar insulins in international and domestic practice of pharmacist
by: I. O. Vlasenko, et al.
Published: (2022-02-01) -
Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients
by: Alexandra Azevedo, et al.
Published: (2018-09-01) -
Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
by: Paweł Kawalec, et al.
Published: (2017-06-01) -
A bibliometric analysis of the global research on biosimilars
by: Akram Hernández-Vásquez, et al.
Published: (2018-12-01)